Johnson & Johnson, Novartis and Astellas all took part in the first close of a round for oncology therapy developer 28-7 Therapeutics that now stands at $82.8m.

US-based cancer drug developer Twentyeight-Seven (28-7) Therapeutics extended a series A round featuring pharmaceutical firms Astellas, Johnson & Johnson and Novartis to $82.8m yesterday. Venture capital firm Sofinnova Partners led a $15m second tranche that included spinout-focused investment firm Osage University Partners. The company had raised an initial $65m in September 2018, from investors including…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.